PBYIPuma Biotechnology, Inc.
$9.98+93% 1Y
$9.98
$4.7352 weeks$9.98
Latest close: a new 52-week highOct 8, 2026what changed →RyuScore 67 of 100: see how it is built 11/19 checks · as of Oct 8, 2026
Price
+93%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: growth
Quality strong, nothing alarming, price roughly fair, growth fading, the market with it.
P/E19.2
Market value$508.0M
1 year+93%
5 years+42%
Charts
As reported to the SEC, without any scoring.
Puma Biotechnology, Inc. (PBYI) reported revenue of $57M in Q2 2026 (quarter ended Jun 30, 2026), up 7.8% from the same quarter a year earlier. That came with a gross margin of 78% and net income of $8.2M (14% of revenue). For the full year FY2025, revenue was $228M (−0.9% year on year) and net income $31M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.